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Abstract: Hashimoto’s thyroiditis (HT) is the most prevalent autoimmune thyroid disorder. Intrathyroidal lymphocytic 
infiltration is followed by a gradual destruction of the thyroid gland which may lead to subclinical or overt 
hypothyroidism. Biochemical markers of the disease are thyroid peroxidase and/or thyroglobulin autoantibodies in the 
serum which are present with a higher prevalence in females than in males and increase with age. Although exact 
mechanisms of aetiology and pathogenesis of the disorder are not completely understood, a strong genetic susceptibility to 
the disease has been confirmed predominantly by family and twin studies. Several genes were shown to be associated with 
the disease occurrence, progression, and severity. Genes for human leukocyte antigen, cytotoxic T lymphocyte antigen-4, 
protein tyrosine phosphatase nonreceptor-type 22, thyroglobulin, vitamin D receptor, and cytokines are considered to be 
of utmost importance. Amongst endogenous factors for the disease development, the attention is focused predominantly 
on female sex, pregnancy with postpartum period and fetal microchimerism. Environmental factors influencing HT 
development are iodine intake, drugs, infections and different chemicals. Disturbed self-tolerance accompanied by the 
increased antigen presentation is a prerequisite for the HT occurrence, whereas proper interaction of thyroid cells, antigen 
presenting cells, and T cells are necessary for the initiation of thyroid autoimmunity. Secreted cytokines lead 
predominantly to T-helper type 1 (Th1) response as well as to Th 17 response which has only recently been implicated. 
Final outcome of HT is thyroid destruction which is mostly a consequence of the apoptotic processes combined with T-
cell mediated cytotoxicity. 
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INTRODUCTION 
  Hashimoto’s thyroiditis (HT) is the most prevalent 
autoimmune thyroid disorder, where lymphocytic infiltration 
of the thyroid gland is often followed by a gradual 
destruction and fibrous replacement of the thyroid 
parenchymal tissue. Patients may or may not develop a 
goitre. The principal biochemical characteristic of the 
disease is the presence of thyroid autoantibodies (TAbs) in 
the patients’ sera against two major thyroid antigens, thyroid 
peroxidase (TPO) and thyroglobulin (Tg). TPO antigen, 
located at the apical membrane of the thyrocyte, is essential 
for thyroid hormone synthesis, catalysis of iodine oxidation, 
iodination of tyrosine residues in Tg and coupling of the 
iodothyrosines into thyroxine (T4) and triiodothyronine (T3). 
The thyroid hormones are synthesized on Tg, a large 
glycoprotein within thyroid follicles, which also serves as 
the storage for thyroid hormones [1]. Small amount of Tg is 
secreted into the circulation where the estimated half-life is 
approximately 3 days [2].
  Antibodies against TPO (TPOAbs) and Tg (TgAbs) are 
of immunoglobulin G class, both showing high affinity for 
their respective antigens. Unlike TgAbs, TPOAbs can 
activate complement and are able to cause damage to thyroid  
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cells due to antibody dependent cell cytotoxicity [3].
Nevertheless, there is little evidence that both antibodies 
have a prime role in the pathogenesis of HT and it is far 
more likely that both T-cell mediated cytotoxicity and 
activation of apoptotic pathways influence the disease 
outcome. However, TAbs serve as a useful marker for the 
diagnosis of thyroid autoimmunity. In HT, TPOAbs are 
present in nearly all (>90 %) patients, while TgAbs can be 
detected in approximately 80% [1, 3].
  The prevalence of HT confirmed by cytology was 13.4% 
in consecutive patients who underwent fine-needle aspiration 
biopsy of thyroid nodules and was similar to that of type 2 
diabetes [4]. Beside lymphoid follicles, changes in epithelial 
cells, formation of connective tissue, and diffuse round cell 
infiltration, in his report Hashimoto described also some 
cracking spaces close to lymphoid follicles. It is now known 
that these cracking spaces are mainly lymphatic vessels, 
localized within the interlobular septa. Their number 
increases within the thyroid parenchyma near the lymphoid 
follicles [5].
  The clinical disease may present with a variety of 
different manifestations ranging from a simple TAbs 
presence in patients with normal thyroid function to the 
development of severe thyroid dysfunction. Some patients 
present with short periods of mild thyrotoxicosis which 
usually cease spontaneously. Most often, euthyroid phase is 
followed by a gradual development of subclinical 
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hypothyroidism with the estimated annual risk of 4% in 
females [6]. According to large epidemiological surveys, HT 
is the most frequent cause of hypothyroidism recorded in 4% 
to 9.5% of the adult population [7-10]. The prevalence of HT 
is high which was also confirmed by the largest National 
Health and Nutrition Examination Survey (NHANES) III 
study. The results show that 18% of the population without 
previously known thyroid disease regardless age or gender 
presented with elevated TAbs; TPOAbs were positive in 
11.3% and TgAbs in 10.4%. The prevalence of TAbs in 
females was twice as high as in males. It increased with age 
and was significantly higher in whites or Japanese than in 
blacks or Mexican Americans [8, 11]. Thus, approximately 
20% of females older than 60 years were TAbs positive [8].
  In spite of a very high HT prevalence, the exact 
mechanisms responsible for the disease development are still 
not completely understood. However, in the last decade there 
has been a significant advancement in the knowledge of the 
aetiology and pathogenesis of autoimmune thyroid disease 
which most frequently occurs in the form of HT or Graves’ 
disease (GD). In this review we discuss the current evidence 
of the possible triggers provoking HT in susceptible 
individuals and putative mechanisms leading to thyroid 
destruction in HT patients. 
GENETIC SUSCEPTIBILITY 
Epidemiological Evidence 
  For several decades a strong genetic predisposition to 
autoimmune thyroid disease has been recognised, 
predominantly on the basis of the family and twin studies. 
Nearly 50 years ago, soon after the discovery of TAbs, the 
presence of TAbs was reported in 56% of siblings of patients 
with autoimmune thyroid disease [12]. This familial 
clustering of autoimmune thyroid disease and the presence of 
TAbs in up to 60% of first-degree relatives of patients has 
been later confirmed by several studies [13-17]. When both 
parents were affected, the prevalence of TPOAbs and TgAbs 
was 42% in daughters and 33% in sons, compared with 
28.9% and 16.7%, respectively, when only one parent was 
TAb-positive [14]. Among first-degree relatives of children 
with HT, 34% were diagnosed TPOAbs positive compared 
to only 13% first-degree relatives of children without 
autoimmune thyroid disease [17]. The sibling risk ratio for 
HT, calculated on the basis of the data from the NHANES III 
study, was 28, thus confirming the highly significant 
contribution of genetic factors to the disease development 
[18]. Recent data from Germany also indicate 32-fold 
increased risk for developing HT in children and 21-fold 
increased risk in siblings of patients with HT, with females 
being significantly more often affected than males [19].
  Twin studies provided further valuable data on the 
genetic contribution to thyroid autoimmunity. In healthy 
twin siblings of patients with overt autoimmune thyroid 
disease, positive TPOAbs and TgAbs in monozygotic twins 
were determined in 53% and 47%, respectively, in dizygotic 
twins in 22% and 13%, respectively, while in healthy control 
population only in 9% and 7%, respectively [20]. The 
concordance rates for TPOAbs were 64% in monozygotic 
twins compared with 35% in dizygotic twins, while 
concordance rates for TgAbs were 74% and 32%, 
respectively [21]. The concordant rate for overt Hashimoto’s 
hypothyroidism was 55% in monozygotic twins and 0% in 
dizygotic twins [22], indicating the importance of non-
genetic influences on the disease development. As assessed 
by a study of Danish twins, 73% of the susceptibility to the 
development of TAbs seems to be attributable to the genetic 
factors [23]. Moreover, a recent twin study indicated that the 
liability to the production of antibodies directed against 
immunodominant region A of TPO is genetically determined 
[24].
Susceptibility Genes 
Human Leukocyte Antigen (HLA) Genes 
  The first gene locus identified in association with the 
autoimmune thyroid disease was major histocompatibility 
complex (MHC) region on the chromosome 6p21 which 
encodes human leukocyte antigens (HLAs). HLA region, 
which is highly polymorphic, comprises several immune 
response genes. HLA molecule, located on antigen 
presenting cell (APC), binds and presents an antigenic 
peptide and in this way enables T cell recognition and 
response to an antigen. Presumably, specific HLA alleles 
have a higher affinity for autoantigenic thyroidal peptides 
and are thus likely to contribute to the development of the 
autoimmune thyroid disease. Nevertheless, in order to 
initiate the thyroid autoimmunity autoantigen occurrence 
within thyroid or thyroid draining lymph nodes is needed, 
being followed by HLA presentation. In HT, aberrant 
expression of HLA class II molecules on thyrocytes has been 
demonstrated. Presumably, such thyrocytes may act as APCs 
capable of presenting the thyroid autoantigens and initiating 
autoimmune thyroid disease [25].
  While in GD, HLA-DR3 was reported by several studies 
as primary susceptibility allele, no consistent associations 
were observed in HT. In Caucasians, associations of 
different forms of HT with various HLA alleles were 
reported, including DR3 [26], DR5, DQ7 [27], DQB1*03
[28], DQw7 [29] or DRB1*04-DQB1*0301 haplotype [30].
In Japanese, associations with DRB4*0101, HLA-A2 [31]
and  DRw53 [32] were demonstrated, while in Chinese 
patients association with DRw9 was observed [33].
Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Gene 
 CTLA-4 gene, which is the second major immune-
regulatory gene related to autoimmune thyroid disease, lies 
on chromosome 2q33. The expression of CTLA-4 on the 
surface of T cells, induced by the activation of the T-cell 
receptor, results in suppression of T-cell activation. CTLA-4
gene polymorphisms may reduce expression or function of 
the CTLA-4 antigen and may therefore contribute to the 
reduced inhibition of T-cell proliferation and subsequently 
increase susceptibility to autoimmune response. In the past, 
several polymorphisms of the CTLA-4 gene in HT patients 
were studied. Among them, the initially reported (AT)n 
microsatellite CTLA-4 polymorphism in the 3’ untranslated 
region (UTR) was found to be associated with HT in 
Caucasian [34] and Japanese patients [35], but not in Italian 
population  [30]. In the exon 1 located 49A/G single 
nucleotide polymorphism (SNP), resulting in threonine to 
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however, certain other studies have not confirmed this 
observation  [30, 39-41]. A large meta-analysis, including 
both published and unpublished data of 866 HT patients, 
indicated a significant association with 49A/G (summary OR 
1.29; 95% CI, 1.11-1.50) [42]. Another CTLA-4
polymorphism is 6230A/G SNP which is located at 3’-UTR 
and designated CT60 [43]. Initial observation of the 
association with HT [43, 44] was not confirmed by later 
studies, including ours [41, 45], however, the results of the 
meta-analysis, based on six published and unpublished 
studies of 839 HT patients, indicated a significant 
association with CT60 SNP (summary OR 1.64; 95% CI, 
1.18-2.28)  [42]. Nevertheless, the exact mechanism 
conferring the susceptibility to HT has not been elucidated 
yet and further studies are needed to determine which CTLA-
4 polymorphism is causative.  
  Aside from being associated with HT, CTLA-4 seems to 
be the major TAb susceptibility gene. A decade ago, a 
linkage of the CTLA-4 region to the presence of TAbs was 
demonstrated by a whole genome linkage analysis [46] and 
subsequently,  CTLA-4 was confirmed as a main locus for 
TAb status also in a larger data set [47, 48]. Evidence 
provided by our studies of Slovenian HT patients indicated a 
strong association between TAb production and the three 
CTLA-4 SNPs, including -318C/T in the promoter, 49A/G 
and  CT60. In patients carrying one of those three SNPs, 
evidently higher TPOAb concentrations were demonstrated 
in relation to the polymorphous CTLA-4 gene, while the 
association with the TgAb concentrations was weaker [49, 
50].
Protein Tyrosine Phosphatase Nonreceptor-Type 22 
(PTPN22) Gene 
 PTPN22 is the most recently identified immune-
regulatory gene associated with the autoimmune thyroid 
disease, which is located on chromosome 1p13. PTPN22, 
which is predominantly expressed in lymphocytes, acts as a 
negative regulator of T-cell activation, much like CTLA-4. 
1858C/T SNP of the PTPN22 gene, resulting in arginine to 
tryptophan substitution at codon 620 (R620W), was 
demonstrated to be a risk factor for many autoimmune 
diseases. The mechanism is not clear since the disease 
predisposing T allele has been demonstrated to enable even 
more efficient inhibition of T-cell activation. Presumably, 
weaker T-cell signalling may lead to impaired thymic 
deletion of autoreactive T cells or an increased PTPN22 
function may result in inhibition of regulatory T cells 
(Tregs), which protect against autoimmunity [51]. An early 
study in HT patients demonstrated a significant association 
with 1858C/T SNP (OR 1.77; 95% CI, 1.56-3.97) [52].
Afterwards, this observation was neither confirmed in 
German, Tunisian and Japanese populations [53-55] nor in 
Slovenian patients included in our study (unpublished data). 
In a small group of patients with both HT and autoimmune 
diabetes, T allele was determined in 50% compared with 
only 14% in healthy controls (OR 6.14; CI, 2.62-14.38) [56],
however, in a yet another study estimating the same 
polymorphism this association was not confirmed [57].
Recently, 5 other PTPN22 SNPs have been tested in 
Japanese patients, showing no relation with HT, but a novel 
protective haplotype containing those SNPs has been 
observed [58].
Thyroglobulin Gene 
  As discussed previously, Tg is an important thyroid 
specific antigen, also present in the circulation, which makes 
it an easy target of the autoimmune response. Gene for Tg is 
located on the chromosome 8q24 and linkage of this region 
with HT and autoimmune thyroid disease was first identified 
by a Japanese and an American whole genome studies [59, 
60]. A subsequent fine mapping of this region exposed Tg
gene as one of the major thyroid specific susceptibility 
genes, linked and associated with the autoimmune thyroid 
disease [61]. Later, different alleles of various microsatellite 
markers and different SNPs of Tg gene were related to HT, 
possibly affecting its expression, antigenicity, iodination, or 
binding to HLA. The association of Tgms2 microsatellite 
marker in intron 27 with HT was confirmed in Japanese [62]
as well as in Caucasian population [63]. Sequencing of 
human  Tg revealed 14 SNPs among which four SNPs, 
including exon 10-12 SNP cluster and exon 33 SNP, were 
associated with HT [64]. However, this observation was 
neither confirmed in a larger data set of the United Kingdom 
Caucasian patients [65] nor in Chinese population, although 
in the later study one haplotype was significantly associated 
with HT and TgAb positivity [66].
Vitamin D Receptor Gene 
  Vitamin D, which acts via vitamin D receptor (VDR), 
possesses immunomodulatory properties and its deficiency 
has been implicated in the development of autoimmune 
diseases. Many immune cells express VDR, dendritic cells in 
particular, where VDR stimulation has been shown to 
enhance their tolerogenicity. Tolerogenic dendritic cells 
promote development of Tregs with suppressive activity and 
therefore peripheral tolerance [67]. VDR gene is located on 
the chromosome 12q12 and its polymorphisms have been 
related to different autoimmune disorders such as type I 
diabetes or Addison’s disease. A decade ago, the association 
between  VDR-FokI SNP in exon 2 and HT has been 
identified [68] which was later confirmed in the observation 
of Taiwanese Chinese patients [69]. In the Croatian 
population VDR gene 3’ region polymorphisms were related 
to HT, possibly affecting VDR mRNA expression [70]. A 
significant relation has also been discovered between HT and 
both promoter and intron 6 gene polymorphisms of 
CYP27B1 hydroxylase, which is located on chromosome 
12q13, catalysing the conversion of 25 hydroxyvitamin D3 to 
its active form [71].
Cytokine Genes and other Immune-Related Genes 
  Lately, several genes encoding different inflammatory 
cytokines have been studied in HT, some of them also 
influencing the severity of the disease. Interferon (IFN)- ,
produced by T-helper type 1 (Th1) cells, promotes cell-
mediated cytotoxicity which underlies thyroid destruction in 
HT. T allele of the +874A/T IFN-  SNP, causing the 
increased production of IFN- , was associated with severity 
of hypothyroidism in HT patients [72]. Higher frequency of 
severe hypothyroidism was also observed in patients 
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leading to a lower production of IL-4, one of the key Th2 
cytokines which suppresses cell-mediated autoimmunity 
[73]. Gene polymorphism of transforming growth factor 
(TGF)- , inhibitor of cytokine production, was also 
associated with HT. T allele of +369T/C SNP, leading to a 
lower secretion of TGF- , was more frequent in severe 
hypothyroidism than in mild hypothyroidism [74]. Similarly, 
more severe form of HT was associated with -2383C/T SNP 
of gene for forkhead box P3 (FoxP3), an essential regulatory 
factor for the Tregs development [75]. Unlike the severity of 
hypothyroidism, the development of HT itself was associated 
with C allele of tumor necrosis factor (TNF)- -1031T/C 
SNP. Namely, C-allele carriers present with higher 
concentration of TNF- which acts as the stimulator of the 
IFN-  production [76].
THE ROLE OF FEMALE SEX AND REPRODUCTION 
Female Sex 
  As indicated by numerous epidemiological studies, 
females present with positive TAbs up to three times more 
often than males [7, 8, 11, 77-81]. The largest NHANES III 
study has shown that females were positive for TPOAbs and 
TgAbs in 17% and 15.2%, respectively, while males only in 
8.7% and 7.6%, respectively [8]. According to the estimation 
provided by the study of Danish twins, the genetic 
contribution to TPOAb and TgAb susceptibility in females 
was 72% and 75%, respectively, while in males it was only 
61% and 39%, respectively [23]. The possible explanation 
for high female predominance in thyroid autoimmunity 
might be associated with the X chromosome containing a 
number of sex and immune-related genes which are of key 
importance in the preservation of immune tolerance [82].
Increased immunoreactivity might therefore be related to 
genetic defects of the X chromosome, such as structural 
abnormalities or monosomy. Accordingly, a higher incidence 
of thyroid autoimmunity was reported in patients with a 
higher rate of X chromosome monosomy in peripheral white 
blood cells [83] or in patients with Turner’s syndrome [84].
Another potential mechanism of impaired immunotolerance 
in females is skewed X-chromosome inactivation (XCI) 
leading to the escape of X-linked self-antigens from 
presentation in thymus with subsequent loss of T-cell 
tolerance. Skewed XCI was associated with a higher risk of 
developing autoimmune thyroid diseases. Recently reported 
frequencies of skewed XCI in HT were 31%, 34.3%, 25.6% 
and 20%, respectively, which is significantly higher than in 
healthy controls, where the prevalences were only 8%, 8%, 
8.6% and 11.2%, respectively [85-88]. Furthermore, a study 
of Danish twins demonstrated a significant association of 
skewed XCI with TPOAb serum concentrations in dizygotic 
but not in monozygotic twin pairs, indicating that shared 
genetic determinants of XCI pattern and TPOAb production 
are more likely than causal relationship [89].
Pregnancy and Postpartum Period 
  The tolerance of the fetal semi-allograft during 
pregnancy is enabled by the state of immunosuppression 
which is a result of hormonal changes and trophoblast 
expression of key immunomodulatory molecules. The 
pivotal players in regulation of the immune response are 
Tregs, which rapidly increase during pregnancy. 
Consequently, both cell-mediated and humoral immune 
responses are attenuated with a shift towards humoral 
immune response, resulting in immune tolerance of the 
conceptus tissues and suppression of autoimmunity [90, 91].
Accordingly, the decrease of both TPOAb and TgAb 
concentrations during pregnancy has been reported, reaching 
the lowest values in the third trimester [91-94].
  Postpartum rapid decrease of Tregs and re-establishment 
of the immune response to the pre-pregnancy state may lead 
to the occurrence or aggravation of the autoimmune thyroid 
disease  [91]. The increase of TPOAb concentrations 
occurred as soon as 6 weeks after delivery [94], reaching the 
baseline level at approximately 12 weeks and the maximum 
level at about 20 weeks after delivery [92, 93]. In up to 50% 
of females with positive TPOAbs in the early pregnancy, 
thyroid autoimmunity in the postpartum period exacerbates 
in the form of postpartum thyroiditis. It may occur within the 
first year after delivery, usually clinically presented with 
transient thyrotoxicosis and/or transient hypothyroidism, 
while in about a third of females permanent hypothyroidism 
may even develop [95]. Interestingly, a significantly higher 
secretion of IFN-  and IL-4 together with a lower median 
plasma cortisol concentration in 36
th week of gestation has 
been reported in females with postpartum thyroiditis than in 
euthyroid females, indicating that weaker immunosupression 
in the former group of females in late pregnancy could 
contribute to the postpartum thyroid dysfunction [96].
Fetal Microchimerism  
  The term fetal microchimerism is defined by the presence 
of fetal cells in maternal tissues which are transferred in the 
maternal circulation during pregnancy. Several years after 
the delivery, the chimeric male cells can be detected in the 
maternal peripheral blood [97, 98] as well as in maternal 
tissues, such as thyroid, lung, skin, or lymph nodes [99]. The 
fetal immune cells, settled in the maternal thyroid gland, 
may become activated in the postpartum period when the 
immunotolerance ceases, representing a possible trigger that 
may initiate or exaggerate the autoimmune thyroid disease. 
In HT, fetal microchimeric cells were detected in thyroid in 
28% to 83% [100-103] which means that their occurrence is 
significantly higher than in the absence of autoimmune 
thyroid disease. Furthermore, a recent study of twins 
supported the putative role of microchimerism in triggering 
thyroid autoimmunity, showing a significantly higher 
prevalence of TAbs in opposite sex twins compared to 
monozygotic twins [104]. Additionally, euthyroid females 
having been pregnant presented significantly more often 
with positive TPOAb compared to females with no history of 
being pregnant [105]. However, the relation between parity 
and autoimmune thyroid disease was not confirmed by large 
population-based studies, advocating against the essential 
contribution of fetal microchimerism to the pathogenesis of 
autoimmune thyroid disease [106-109].
ENVIRONMENTAL TRIGGERS 
Iodine Intake 
  Excessive iodine intake is well-established environmental 
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population-based studies demonstrated higher prevalence of 
TAbs in the areas with higher iodine supply since the 
estimated prevalence was approximately 13% in iodine 
deficiency  [7], 18% in circumstances of sufficient iodine 
intake  [8] and about 25% in areas with excessive iodine 
intake [11]. Moreover, up to four-fold increase in prevalence 
of TAbs was demonstrated after the exposure to higher 
iodine intake due to the improvement of iodine prophylaxis 
in previously iodine deficient areas [110-112]. According to 
the intervention study, deliberate exposure to 500  g of 
iodine provoked thyroid autoimmunity in 20% of previously 
healthy individuals [113]. Valuable evidence was also 
provided by using experimental animal models of 
autoimmune thyroiditis, where the prevalence and severity of 
thyroid autoimmunity significantly increased when the 
dietary iodine was added [114].
  Several putative mechanisms by which iodine may 
promote thyroid autoimmunity have been proposed. Firstly, 
iodine exposure leads to higher iodination of Tg and thus 
increases its immunogenicity by creating novel iodine-
containing epitopes or exposing cryptic epitopes. This may 
facilitate presentation by APC and enhance the binding 
affinity of the T-cell receptor which may lead to specific T-
cell activation [114]. Secondly, iodine exposure has been 
shown to increase the level of reactive oxygen species in the 
thyrocyte which is generated during TPO oxidation of 
excessive amounts of iodine. They enhance the expression of 
the intracellular adhesion molecule-1 (ICAM-1) on the 
thyroid follicular cells which could attract the 
immunocompetent cells into the thyroid gland [115].
Thirdly, iodine toxicity to thyrocytes has been reported, 
since highly reactive oxygen species may bind to membrane 
lipids and proteins, causing thyrocyte damage and release of 
autoantigens [112]. Fourthly, iodine excess has been shown 
to promote follicular cell apoptosis by inducing an abnormal 
expression of tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) and its death receptor (DR)-5 in 
thyroid  [116]. Fifthly, in vitro evidence also suggests an 
enhancing influence of iodine on the cells of the immune 
system, including augmented maturation of dendritic cells, 
increased number of T cells and stimulated B-cell 
immunoglobulin production [112].
Drugs 
  Furthermore, certain drugs were reported to trigger or 
exacerbate thyroid autoimmunity in susceptible individuals. 
Interferon   (IFN-) is extensively used to treat chronic 
hepatitis and is frequently associated with thyroid 
autoimmunity since TAbs were observed in up to 40% and 
clinical disease in 5-10% of patients treated with IFN-.
Presumably, IFN- has both thyroid toxic effects with 
consequent autoantigen presentation and immune effects, 
such as switching to Th1 immune response, suppression of 
Treg function, activation of immune cells, stimulation of 
cytokine release and expression of MHC class I on thyroid 
cells  [117]. Similarly, IL-2 treatment, used for melanoma 
and renal carcinoma, seems to act via  immune and toxic 
mechanisms, leading to both TAb positivity and 
hypothyroidism [118]. In patients with known autoimmune 
thyroid disease lithium may increase the risk of 
hypothyroidism. According to some studies, treatment with 
lithium has also been shown to increase TAb titres and the 
prevalence of thyroid autoimmunity, although this 
observation has not yet been confirmed by other reports 
[118, 119]. Among putative mechanisms direct toxicity of 
lithium on thyroid or toxicity of increased intrathyroidal 
iodine resulting from lithium treatment were discussed [118].
Similarly, amiodarone alone as well as its high iodine 
content may act cytotoxically which may lead to thyroid 
autoantigen presentation and provoke thyroid autoimmunity 
[120].
Infections 
  Not only the IFN- treatment but also hepatitis C 
infection itself has been reportedly associated with thyroid 
autoimmunity and hypothyroidism. Among possible 
mechanisms, the molecular mimicry between viral and self-
antigens has been suggested, whereas the release of pro-
inflammatory mediators caused by viral infection may lead 
to activation of autoreactive T-cells [117]. Besides, in HT 
several other putative triggering viruses have been 
implicated such as parvovirus, rubella, herpes simplex virus, 
Epstein Barr virus, and human T-lymphotropic virus type 1 
[121]. A recent study of sera in pregnant women has also 
indicated an association between a prior infection with 
Toxoplasma gondii and an increase of TPOAbs [122].
Nevertheless, the evidences are scarce and further studies are 
required in order to confirm the role of infections as 
causative agents.  
Chemicals 
  The exposure to environmental toxicants such as 
polyaromatic hydrocarbons or polyhalogenated biphenyls, 
both commonly used in a variety of industrial applications, 
has been shown to provoke thyroid autoimmunity not only in 
experimental animals but also in humans [115]. Recently, a 
significantly higher prevalence of HT and TAb (9.3% and 
17.6%, respectively) has been demonstrated in residents 
living in the area of petrochemical complex of Sao Paolo 
compared to the control area (3.9% and 10.3%, respectively) 
[123]. In Slovakia, the exposure to polychlorinated biphenyls 
was associated with TAb and hypothyroidism [124].
Although there is strong evidence attesting the contribution 
of chemicals to thyroid autoimmunity, the exact mechanisms 
of their action are yet to be established. 
PROTECTION AGAINST THYROID AUTOIM-
MUNITY 
  Two mechanisms enable the maintenance of self-
tolerance. The central tolerance refers to thymic deletion of 
autoreactive T cells during fetal life. Those cells that escape 
central tolerance are prevented from triggering autoimmunity 
by mechanisms of peripheral tolerance where the pivotal role 
is played by Tregs [91, 125]. They have a suppressive effect 
on the effector T cells, APCs and B cells, therefore 
maintaining the immunological unresponsiveness to self-
antigens and suppressing the excessive immune response 
[126]. They may directly suppress target cells or act through 
secreted suppressor cytokines.  
  Tregs derive from thymus as a subpopulation of T cells 
or from naive T cells in the periphery and express CD25 (Hashimoto’s Thyroiditis  Current Genomics, 2011, Vol. 12, No. 8    581
chain of the IL-2 receptor) and FoxP3. Therefore, the critical 




Tregs [125]. Cells with the highest CD25 expression 
(CD4+CD25high) are responsible for regulatory suppressive 
effects [127]. The role of Tregs in self-tolerance was 
extensively studied in animal models, especially on murine 
experimental autoimmune thyroiditis, where the protection 




+ Tregs [128]. In humans, CD25 
expression was higher in patients with HT than in healthy 
subjects [129]. When patients with autoimmune thyroid 
disease were studied, the proportion of Tregs was lower 
intrathyroidally than in peripheral blood [130]. When 
compared to controls, a higher proportion of special Tregs 
with high levels of FoxP3 (termed CD4+CD25highHLA-
DR+ cells) in HT patients was found by three-color flow 
cytometry [131]. This indicates a compensatory expansion of 
Tregs subpopulation in order to diminish the immune 
response [132].  
  The expression of Foxp3 and generation of Treg cells are 
both induced by TGF- produced in Tregs, fibroblasts, 
macrophages, endothelial cells in inflammatory thyroid 
tissue as well as in thyrocytes [133, 134]. TGF- is a key 
regulator of immune tolerance which stimulates suppressive 
Tregs and inhibits T cell differentiation [134]. Accordingly, 
in patients with HT, serum levels of TGF- were lower than 
in controls which did not change after the treatment with 
levothyroxine. Therefore, levels of TGF- s e e m  t o  b e  
associated with the HT and not thyroid dysfunction [135]. 
Suppressive effect of TGF- was established in the 
development of experimental autoimmune thyroiditis [136]. 
At the later stage of the thyroiditis TGF- may trigger the 
development of fibrosis [137].  
DEVELOPMENT OF THYROID AUTOIMMUNITY 
  For the initiation of thyroid autoimmunity the proper 
interaction of thyroid cells, APCs, and T cells is necessary. 
The result is a secretion of different cytokines leading to Th1 
response which is characteristic of HT. Cytokines have an 
important role in autoimmune thyroid disease and are 
secreted by the immune cells, thyroid follicular cells, and 
inflammatory cells [138]. In spite of the extensive researches 
in last decades, the exact mechanisms of initiation and 
progression of thyroid autoimmunity have not been 
completely clarified yet.  
  T lymphocyte proliferates and secretes cytokines after 
being stimulated by two signals. First signal is the activation 
of T-cell receptor which is induced by binding of antigen 
peptide presented on HLA molecule on the surface of APC. 
Second costimulatory signal is ligation of CD28 on the 
surface of T cell to B7 ligands (B7.1 and B7.2) expressed on 
APC, including dendritic cells, activated macrophages, and 
activated B cells. As explained previously, activation of T 
cell induces the expression of CTLA-4 which suppresses 
further T cell activation by binding and blocking of B7 
ligands. In patients with HT, but not in GD or goitrous 
patients, thyroid follicular cells were positive for B7.1 [139]. 
Thyroid follicular cells may also express MHC class II 
molecules induced by IFN-  which is secreted by 
intrathyroidal lymphocytes [140]. Colocalization of MHC 
class II and B7.1 antigens on the same thyroid follicular cell 
indicates that in the pathogenesis of HT follicular cells may 
act also as APCs and may be capable of inducing or 
maintaining the autoimmune process. Besides, the 
interaction between thyroid follicular cells and lymphocytes 
seems to be crucial for the progression of thyroid 
autoimmunity [140].  
  Autoimmune response is predominantly determined by 
the antigen, nature of APC, and several genetic, endogenous, 
and environmental triggers [140]. In HT, where possible 
triggers were previously discussed, autoimmune response is 
mediated predominantly by Th1-type cytokines such as 
TNF-, IFN-  and IL-2 which all participate in the 
pathogenesis in a harmful way (Fig. 1) [141]. According to 
cytokine mRNA profiles, both Th1 and Th2 response were 
supposed to be involved in the pathogenesis of HT with 
deviation toward Th1 pattern [141]. When exposed to a 
thyroid self-antigen such as human Tg, peripheral blood 
mononuclear cells from patients with HT produced more 
TNF-, IL-2, IL-10, IFN- , and less IL-5 than controls. Since 
higher production was observed with autologous sera than 
with pooled normal sera, the importance of serum elements, 
such as the complement and serum anti-Tg activity, was 
proposed. Authors postulated that these two serum elements 
accelerate Th1/Th2 cell cytokine reaction by increasing the 
uptake of autoantigens by APCs [142]. Interestingly, 
peripheral Th1/Th2 ratio seems to also be related to the 
severity of HT since patients with more severe 
hypothyroidism presented with a higher ratio compared with 
those with mild hypothyroidism [143]. Furthermore, the 
correlation between the TPOAb levels and the production of 
TNF- and IFN-  has been demonstrated [144] and recently 
confirmed by a study indicating that TPOAbs seem to 
promote TPO-elicited cytokine production, including IFN- ,
TNF-, and IL-6 [145].  
  In the past few years, a new subset of Th cells, 
designated Th17, has been studied. Th17 cells have also 
been proved highly proinflammatory and may lead to 
autoimmunity in animal models and potentially also in 
human autoimmune diseases [134]. A putative importance of 
Th17 in the pathogenesis of HT has been indicated by a 
recent study showing increased levels of Th17 lymphocytes 
and Th17 cytokines compared with healthy controls [146]. 
Similarly, when estimating the expression in peripheral 
blood mononuclear cells, Th17 cells rather than Th1 cells 
predominated in HT patients [147]. 
THYROID DESTRUCTION 
  Thyroid destruction in HT is mostly a consequence of the 
apoptotic processes combined with CD8+ cell mediated 
cytotoxicity, changes in cell junctions, and complement 
activation.  
  Apoptosis is characterized by cytoskeletal disruption, cell 
shrinkage, chromatin condensation, nuclear fragmentation, 
membrane blebbing, and DNA fragmentation [148]. In 
general, apoptosis enables adult healthy tissue homeostasis, 
while excessive cell death causes a loss of active tissue and 
an impaired function [148]. Two major apoptotic signal 
pathways have been studied more thoroughly [149]. The first 
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transmembrane protein and a member of TNF receptor 
superfamily, and Fas ligand, a type II transmembrane protein 
which binds to Fas receptor and activates apoptotic process 
[150]. The second pathway includes TRAIL (Apo2L), a 
member of TNF receptor family which activates apoptosis 
by binding to its receptors TRAIL-R1 (DR4) and TRAIL-R2 
(DR5) [151, 152]. Both pathways lead to the activation of 
proteolytic enzymes caspases which destroy thyroid cells. In 
normal circumstances, the Fas pathway is inhibited, whereas 
in inflammation, it is activated by cytokines [153]. In vitro 
studies have shown that TSH inhibited Fas-mediated 
apoptosis, while the absence of TSH induced apoptosis 
[154]. A combination of IFN-  with TNF- or IL-1
stimulated the Fas-activated apoptosis in cultured thyroid 
follicular cells [155]. TRAIL receptors are also expressed in 
thyroid cells by cytokines [156]. TRAIL could mediate the 
programmed cell death under appropriate conditions [157]. 
Thyroid follicular cells were able to express TRAIL in the 
presence of IFN- , TNF-, and IL-1 in vitro. Thus, 
inflammatory cytokines such as IFN- , TNF-, and IL-1 can 
influence immune-mediated apoptosis [156]. Additional 
inductor of programmed cell death is TGF- [158]. Its 
release from thyroid cells is stimulated by the epidermal 
growth factor (EGF) [159]. In porcine thyroid follicles both 
TGF- and EGF induced apoptosis, the latter probably also 
by its influence on TGF- expression [160]. Therefore, the 
mechanism of apoptosis in HT seems to be induced by 
cytokines secreted from local lymphocytes [161].  
  In HT, the main apoptotic mechanism represents Fas-
mediated apoptosis together with downregulation of Bcl-2 
which is an inhibitor of apoptosis highly expressed in normal 
thyrocytes [162-165]. Bcl-2 immunostaining was high in 
healthy thyroid follicles and in follicles away from 
lymphocytic infiltrates in HT, but weak in thyroid follicles 
surrounded by lymphocytic infiltrates in thyroid glands with 
HT [163]. Immunohistochemically, patients with HT had a 
lower percentage of Bcl-2 stainings and a higher percentage 
of caspase-3 reactions than control subjects [166]. In thyroid 
glands with HT, a strong staining for Fas and Fas ligand and 
a high percentage of apoptosis was observed in thyroid 
follicles adjacent to lymphocytes when compared with 
healthy thyroid tissue where a moderate, minimal, or no Fas 
ligand and almost no apoptosis were found. In HT, there was 
also a higher number of CD8+ cells expressing Fas found 
than in healthy subjects [164].  
  Beside apoptosis, CD8+ cell mediated cytotoxicity 
contributes to thyroid destruction mediated by ICAM-1 
Fig. (1). Mechanisms of thyroid autoimmunity in HT. In individuals with certain genetic background, several endogenous and environmental 
factors may trigger thyroid autoimmunity, causing increased antigen presentation in the thyroid and consequently leading to reduced immune 
tolerance. As a result, different cytokines are produced by immune and thyroid cells leading to predominantly Th1 response with increased 
Th1/Th2 ratio. Lately, also Th17 effector T cells have been implicated in thyroid autoimmunity. Increased production of cytokines, such as 
interferon   (IFN- ), tumor necrosis factor  (TNF-), and interleukin 1 (IL-1), may lead to apoptotic processes which combined with CD8+ 
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which is expressed by thyroid follicular cells and increases 
CD8+ cell binding [140]. Levels of ICAM-1, vascular cell 
adhesion molecule-1 (VCAM-1), and tissue inhibitor of 
metalloproteinases 1 (TIMP-1) were significantly higher in 
patients with functional abnormality due to the autoimmune 
thyroid disease than in euthyroid subjects. Authors 
postulated that autoimmune process itself may have an 
impact on vascular inflammation, endothelial dysfunction, 
and tissue remodelling [167].  
  Finally, changes in gap junctions consequently leading to 
cell-to-cell communication changes may contribute to the 
thyroid destruction. In HT, decreased levels of connexin 43 
(Cx43) were observed immunohistochemically when 
compared with the normal thyroid tissue [168]. Cx43 is a 
part of connexons which constitute a gap junction channel in 
organized tissues as well as in thyroid tissues. Similarly, 
reduced proteins Cx43, Cx32, and Cx26 were established in 
animal models of autoimmune thyroid disease [169]. Studies 
also showed that T3 increased the level of Cx43 [170]. 
Therefore, the number of gap junctions may be increased in 
GD and decreased in HT [168]. Disruption of thyroid 
integrity may allow TPO antibodies to bind to TPO and 
activate complement [140].  
CONCLUSION 
  HT is one of the most prevalent autoimmune diseases 
provoked in genetically susceptible individuals by several 
triggers, including female sex, immune changes after 
delivery, fetal microchimerism, iodine intake, and other 
environmental factors. Multiple susceptibility genes may be 
involved in the disease development, some of which are also 
common for other autoimmune diseases, while others are 
specific for thyroid autoimmunity. It is now clear that 
immune-regulatory genes such as HLA, CTLA-4, and 
PTPN22 play a major role in the aetiology of HT, GD, and 
several other autoimmune diseases. The only thyroid specific 
gene currently showing the association with HT is gene for 
Tg which is also GD susceptibility gene. VDR gene is 
another HT predisposing gene, common for other organ-
specific autoimmune diseases such as type I diabetes or 
Addison’s disease. Furthermore, recent studies of cytokine 
genes such as IFN- , IL-4, or TGF-  indicate the association 
with the development and severity of HT, presumably 
influencing the balance between Th1 and Th2 mechanisms.  
  According to the current knowledge, a complex 
interaction between genetic and non-genetic factors 
presumably results in enhanced thyroid antigen presentation 
and reduced immune tolerance leading to predominantly 
Th1-type autoimmunity, thyroid destruction, and clinical 
disease. Despite tremendous progress made in the 
understanding of HT during the past decade, the exact 
mechanisms of its progression are yet to be clarified. 
Hopefully, in the near future, new evidence will enable a 
better insight into the disease pathogenesis which may help 
us identify subjects at risk and may be even enable us to 
prevent the development of clinical disease.  
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ABBREVIATIONS 
APC  =  Antigen presenting cell 
CTLA-4  =  Cytotoxic T lymphocyte antigen-4 
DR =  Death  receptor 
FoxP3  =  Forkhead box P3 
GD =  Graves’  disease 
HLA  =  Human leukocyte antigen 
HT =  Hashimoto’s  thyroiditis 
ICAM-1 =  Intracellular  adhesion  molecule-1 
IFN =  Interferon 
IL =  Interleukin 
MHC  =  Major histocompatibility complex 
NHANES  =  National Health and Nutrition Examination 
Survey 
PTPN22  = Protein tyrosine phosphatase nonreceptor-
type 22 
SNP  =  Single nucleotide polymorphism 
TAbs =  Thyroid  autoantibodies 
T4 =  Thyroxine 
Tg =  Thyroglobulin 
TgAbs =  Antibodies  against  Tg 
TGF  =  Transforming growth factor 
TIMP-1  =  Tissue inhibitor of metalloproteinases 1 
Th =  T-helper 
TNF  =  Tumor necrosis factor 
TPO =  Thyroid  peroxidase 
TPOAbs =  Antibodies  against  TPO 
TRAIL  =  Tumor necrosis factor-related apoptosis-
inducing ligand 
Tregs =  Regulatory  T  cells 
T3 =  Triiodothyronine 
UTR =  Untranslated  region 
VCAM-1  =  Vascular cell adhesion molecule-1 
VDR  =  Vitamin D receptor 
XCI =  X-chromosome  inactivation 
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